Tag Archives: ASCO

ASCO Oncology Stocks: Recap and Scoreboard- AGIO, MDVN, SGEN Winners

High Profile Biotechnology Companies with ASCO Presence Investors and traders waited toward the end of the ASCO Annual Meeting week to buy their favorite stocks. The biotech sector overall was boosted after the close of the meeting after a brief sell-off on June 2 and 3. Most biopharmaceutical stocks peaked in late February so ASCO […]

Comments Off Continue Reading →

Very Little Bounce in Biotech as ASCO Approaches… Update 2.. 5/22

Rally Developing-Green Screen Alert If you are underweight large cap biotech add FBT ($76.38) up 2%. Most of our large cap picks are up today: ABBV ALXN, BIIB,GILD,REGN. Reverse pattern from tuesday’s downdraft. ————– One of the worse days I have seen in small cap biotech in many months as speculation has ended and investors […]

Comments Off Continue Reading →

Pre-ASCO Watch List #2: ARIA, IMGN, PCYC

Rayno Life Science Focus Stocks: ARIA, IMGN, PCYC  Ariad (ARIA) Abstracts Several data presentations will be made for Iclusig (Ponatinib)  for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2. Immunogen (IMGN) Abstracts The focus will be on […]

Comments Off Continue Reading →

Pre-ASCO Movers: CLVS, INCY, PBYI

Volatility Up as ASCO Approaches The ASCO Annual Meeting is not till the end of the month but news regarding abstract titles and clinical data that will be presented at ASCO moved stocks today. Many immuno-oncology stocks have been hard hit in the 2014 sell-off as investors have moved out of small  cap speculative growth […]

Comments Off Continue Reading →

Nice Recovery Day Despite Lackluster Tape-Healthcare Lagging Sector

Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the FXI at $31.70 down from the $41 level earlier this year. The […]

Comments Off Continue Reading →

Reiterate Caution on Biopharmaceutical Stocks With Major 3% Sector Sell-Off

Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the news” trend. Moreover CNBC pundits have been pushing biotech […]

Comments Off Continue Reading →